Urogen Pharma’s (URGN) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Urogen Pharma (NASDAQ:URGN) in a research report report published on Friday morning,Benzinga reports. The brokerage currently has a $33.00 price objective on the stock.

A number of other equities analysts have also weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday. Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Urogen Pharma in a report on Monday, October 27th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

Urogen Pharma Stock Performance

Shares of URGN opened at $20.00 on Friday. The stock has a 50 day moving average price of $23.13 and a 200 day moving average price of $20.21. Urogen Pharma has a one year low of $3.42 and a one year high of $30.00. The stock has a market capitalization of $936.20 million, a price-to-earnings ratio of -5.78 and a beta of 1.29.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.03. The firm had revenue of $27.48 million during the quarter, compared to analysts’ expectations of $34.09 million. On average, analysts predict that Urogen Pharma will post -3.12 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Mark Schoenberg sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the transaction, the insider directly owned 139,025 shares in the company, valued at approximately $3,475,625. This represents a 6.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.70% of the company’s stock.

Institutional Investors Weigh In On Urogen Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in URGN. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Urogen Pharma by 148.4% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 161,924 shares of the company’s stock worth $3,792,000 after purchasing an additional 96,741 shares during the period. SG Americas Securities LLC boosted its stake in Urogen Pharma by 19.0% during the fourth quarter. SG Americas Securities LLC now owns 1,377,647 shares of the company’s stock worth $32,264,000 after buying an additional 220,264 shares during the period. JPMorgan Chase & Co. increased its position in shares of Urogen Pharma by 36.9% during the third quarter. JPMorgan Chase & Co. now owns 534,545 shares of the company’s stock valued at $10,664,000 after acquiring an additional 144,181 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Urogen Pharma during the third quarter valued at about $426,000. Finally, TCG Crossover Management LLC purchased a new stake in shares of Urogen Pharma in the 3rd quarter valued at approximately $14,311,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.